Physician profile
Ashlee Ann Walker
NPI 1770207391
$8,406.79
in general payments reported to CMS, 2019-2025
29 companies · $4,504 in 2025
The $4,504 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $316 · 2023: $1,489 · 2024: $2,098 · 2025: $4,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,103 · Travel and Lodging: $957 · Education: $31.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,103.33 |
| Travel and Lodging | $956.88 |
| Education | $31.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $1,666.84 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,445.87 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Abbvie INC. | $1,339.06 | 2023-2025 | |
| Genzyme Corporation | $582.69 | 2022-2025 | |
| Janssen Biotech, INC. | $567.07 | 2023-2025 | Tremfya, Stelara, Simponi |
| Ardelyx, INC. | $326.33 | 2024-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $271.17 | 2023-2025 | Dupixent |
| Madrigal Pharmaceuticals | $233.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $227.37 | 2023-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $176.49 | 2024-2025 | Iqirvo |
| Celgene Corporation | $173.58 | 2023-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $145.87 | 2022-2025 | Ocaliva |
| Aimmune Therapeutics, INC. | $138.22 | 2024-2025 | Vowst, Zenpep |
| Pfizer INC. | $122.33 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.80 | 2023-2025 | Xifaxan |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $113.93 | 2022 | |
| Qol Medical, LLC | $112.88 | 2023-2025 | Sucraid |
| Phathom Pharmaceuticals, INC. | $111.88 | 2024-2025 | Voquezna |
| Lucid Diagnostics INC. | $93.15 | 2023 | |
| Gilead Sciences, INC. | $81.87 | 2023-2025 | |
| Novo Nordisk INC | $64.55 | 2025 | Wegovy |
| Organon LLC | $60.62 | 2023 | Hadlima, Renflexis |
| Boston Scientific Corporation | $56.40 | 2023-2025 | General - Polypectomy |
| Orphalan INC | $48.88 | 2025 | Cuvrior |
| Braintree Laboratories, INC. | $48.62 | 2023-2024 | Sutab, Suflave |
| Mylan Institutional INC. | $30.18 | 2023 | |
| Digestive Care, INC. | $20.53 | 2024 | Pertzye |
| Medtronic, INC. | $17.88 | 2025 | Interstim |
| Daiichi Sankyo INC. | $14.70 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlee Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.